Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
https://www.fool.com/investing/2024/04/15/novo-nordisk-and-ginkgo-bioworks-are-teaming-up/?source=iedfolrf0000001
Apr 15, 2024 - The collaboration could help solve challenges for both businesses.
0
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
https://www.fool.com/investing/2024/04/20/2-everlasting-big-pharma-stocks-to-buy-today-and/?source=iedfolrf0000001
Apr 20, 2024 - These stocks probably won't be getting much cheaper.
0
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
https://www.zacks.com/stock/news/2193099/roche-rhhby-to-acquire-obesity-drug-maker-carmot-for-2-7b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193099
Dec 04, 2023 - Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
0
Centene (CNC) Wins Contract From Arizona's Medicaid Agency
https://www.zacks.com/stock/news/2193148/centene-cnc-wins-contract-from-arizona-s-medicaid-agency?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193148
Dec 04, 2023 - Centene's (CNC) Arizona subsidiary has been chosen by the AHCCCS to improve health outcomes for the state's ALTCS-E/PD members and further solidify statewide presence.
0
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
0
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196713
Dec 12, 2023 - Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
0
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
https://www.zacks.com/stock/news/2197201/is-it-a-good-idea-to-buy-journey-medical-derm-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197201
Dec 13, 2023 - Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.
0
Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2198664/has-arvinas-arvn-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2198664
Dec 15, 2023 - Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
0
5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders
https://www.zacks.com/stock/news/2199250/5-non-u-s-stocks-to-buy-as-wall-street-fires-on-all-cylinders?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199250
Dec 18, 2023 - We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.
0
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200049
Dec 19, 2023 - The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
0